| Description |
| Product Type |
Product Size |
| Tablets |
30'S |
| Product Company |
| PMS Pharma |
Letrozole 2.5mg |
| Product Type |
Product Size |
| Tablets |
30'S |
| Product Company |
| Beacon Pharmaceuticals |
Sorafenib 200mg |
| Product Type |
Product Size |
| Tablet |
60'S |
| Product Company |
| Pharma Solution |
Sorafenib 500mg |
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Pharmasol |
|
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Roche Pharma |
Atezolizumab 1200mg/20ml |
| Product Type |
Product Size |
| Tablet |
30'S |
| Product Company |
| Manufacture Deva Holding / Marketed by Searle |
Letrozole 2.5mg |
| Content | Letrozole is a medicine used for treating breast cancer. It can also help prevent breast cancer coming back. It is mainly prescribed for women who have been through the menopause and have a type of cancer called "hormone-dependent" breast cancer.
| Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body. Sorafenib is an antineoplastic (cancer) agent.
| Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body.
| Vincristine is a chemotherapy drug that belongs to a group of drugs called vinca alkaloids. Vincristine works by stopping the cancer cells from separating into 2 new cells. So, it stops the growth of the cancer. | "
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma, and alveolar soft part sarcoma. | Letrozole is a non-steroidal type II aromatase inhibitor. It blocks the active site, and therefore the electron transfer chain of CYP19A1. This competitive inhibition prevents the conversion of androgens to estrogen. This action leads to a reduction in uterine weight and elevated leuteinizing hormon. |
Reviews
There are no reviews yet.